Pluristem Therapeutics (PSTI) Secures Orphan Drug Designation for Its PLX-R18 Cell Therapy
Tweet Send to a Friend
Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced today that the U.S. Food and Drug Administration (FDA) has granted the company an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE